🇺🇸 FDA

Company profile · Sponsor

Zaklady

Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

EBE8609 · EMA pharma EU
Pipeline
6
Drugs
0
Patents
0

Quick answer

Zaklady (EBE8609) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EBE8609
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (6)

Search pipeline →

  1. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.

    Zaklady

    infection

    phase 1 other active

    1 trial

  2. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated tablets (Polfa Tarchomin S.A., Poland) versus Froxiga 10 mg film-coated tablets (AstraZeneca AB, Sweden) in healthy volunteers under fasting conditions.

    Zaklady

    intended for treatment of for the treatment of (2): • insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. • symptomatic chronic heart failure. • chronic kidney disease.

    phase 1 other active

    1 trial

  3. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-coated tablets versus Augmentin® 500 mg + 125 mg film-coated tablets in healthy volunteers under fed conditions.

    Zaklady

    infections

    phase 1 other active

    1 trial

  4. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.

    Zaklady

    infections

    phase 1 other active

    1 trial

  5. Bioequivalence Study of Empagliflozin

    Zaklady

    Not applicable (submitted trial is a BE study in healthy participants)

    phase 1 other active

    1 trial

  6. Pharmacokinetic study of colistimethate sodium

    Zaklady

    serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options

    phase 1 other active

    1 trial

Frequently asked questions

What is Zaklady?

Zaklady (EBE8609) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Zaklady sponsor?

We track 6 ClinicalTrials.gov-linked programs for Zaklady, including A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions. and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Zaklady company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.